Samsung Electronics
Search results
Samsung Biologics builds stronger connections through bolstered CDO capabilities and continuous expansion | Highlights from BIO 2024. Minimize risk, maximize success: identify high-potential candidates with a robust developability assessment platform with scope expansions.
Samsung Biologics Co., Ltd. is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing (CDMO) services to the biopharmaceutical industry.
Mar 31, 2023 · Samsung Biologics is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing services at every stage for biopharmaceutical products.
Mar 31, 2023 · Find all Investor Relation materials, including our earnings release, stock chart, public disclosures, annual and business reports, and audited financial statements.
2 days ago · Samsung Biologics announced July 2 that it has signed a $1.06 billion contract with a U.S.-based pharmaceutical company for the contract manufacturing of biopharmaceuticals. This is the largest contract ever secured by a South Korean biotech company and represents 42% of Samsung Biologics’ total orders from last year.
3 days ago · In a public disclosure posted Tuesday, Samsung Bio revealed a new manufacturing accord with a large, unnamed U.S. drugmaker worth 1.46 trillion Korean won (about $1.05 billion). The deal ...
Incheon, S. Korea, July 18, 2023 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report.
